FDA Decision on Novartis Drug Is Delayed
14th Nov 2006, 08:33 GMT
Novartis said the FDA will take three months longer than expected to decide on the approval of its experimental diabetes drug Galvus. The delay presents a short-term advantage for rival Merck.
FDA Decision on Novartis Drug Is Delayed related news:
- FDA Extends Novartis Drug Review — WSJ.com: What's News Europe
- Novartis diabetes drug faces three month delay — Pharmaceutical Business Review Latest News
- FDA Review on Novartis Galvus Extended — Government/ Industry Regulation News from StratCenter.com
- U.S. delays Novartis diabetes drug — Marketplace by Bloomberg - International Herald Tribune
- Novartis diabetes drug delayed — FT.com - Companies
- Novartis announces three-month extension of US regulatory review for Galvus® to assess recently available clinical data — WebWire - Recent Headlines
- Novartis Diebetes Drug Gets FDA Setback — StratWire - Business of Healthcare NewsFeed
- FDA Urges Caution on Flu Drug — WSJ.com: What's News US
- FDA Suggests New Tamiflu Warning — WSJ.com: What's News US
- FDA Orders Caution Over the use of Tamiflu — NPR Topics: Nation
Latest news from WSJ.com: What's News Europe:
- Deutsche Telekom CEO Resigns
- European Shares Gain Ground
- Arcelor Mittal Says Dofasco Sale Is Thwarted
- U.K. Life-Insurance Market May Shrink
- Two Italian Banks Discuss Merger
- FDA Extends Novartis Drug Review
- European Shares Gain Ground
- Qualcomm, Nokia Deal Is Unlikely
- BPU Board Backs Purchase of Rival
- Marshall Wace Plans Hedge-Fund IPO